Optimizing Fludarabine: The Impact of Fludarabine Renal Dose Adjustment during Lymphodepletion Prior to CAR-T cell Immunotherapy in Multiple Myeloma Patients

Key Points

• Improved outcomes from renal dose adjustments of fludarabine were observed in multiple myeloma patients receiving CAR-T cell therapy.
• Key findings indicated that patients with adjusted doses showed reduced adverse effects, enhancing overall treatment tolerance.
• Analysis was based on a cohort of multiple myeloma patients undergoing lymphodepletion with varying fludarabine doses.
• This research may support personalized dosing strategies to optimize immunotherapy effectiveness and safety for multiple myeloma patients.